Clinical Trial Update: VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating VESICARE (solifenacin) for improving overactive bladder symptoms in patients undergoing image-guided radiotherapy for prostate cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Vesicare (solifenacin succinate)

Snippet

Sponsor: Advanced Research Network | Conditions: Over-Active Bladder | Phase 4 | Status: TERMINATED | Results posted: 2015-01-16